MAM
ABCL icon

Myriad Asset Management’s AbCellera Biologics ABCL Stock Holding History

Myriad Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,000
Closed -$501K – 151
2021
Q3 		$501K Buy
+25,000
New +$442K 0.05% 114

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Myriad Asset Management's ABCL Position: Q4 2021 in Review

Myriad Asset Management sold out of AbCellera Biologics (ABCL) in Q4 2021, closing a stake of 25,000 shares — an estimated $501K sold.

Myriad Asset Management first reported a position in ABCL in Q3 2021 and held it in 1 quarter. The position peaked at $501K in Q3 2021. 124 funds tracked by Wall St. Rank hold ABCL as of Q4 2021.

  • Myriad Asset Management reported no remaining AbCellera Biologics position as of Q4 2021 after selling out during the quarter.
  • Myriad Asset Management sold 25,000 AbCellera Biologics shares in Q4 2021, an estimated $501K.
  • Myriad Asset Management first reported a position in AbCellera Biologics in Q3 2021 and held it in 1 quarter.
  • Myriad Asset Management's AbCellera Biologics position peaked at $501K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2021.

Based on Myriad Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.